Tirzepatide treatment and achieving weight reduction >5%, SBP reduction >5 mmHg and non-HDL cholesterol reduction >10%: A post hoc analysis from the SURMOUNT-1 3-year trial

Back

ESC2025 Premium Access

Tirzepatide treatment and achieving weight reduction >5%, SBP reduction >5 mmHg and non-HDL cholesterol reduction >10%: A post hoc analysis from the SURMOUNT-1 3-year trial

Session: Obesity (1)

Topic: Obesity

Speaker: Professor N. Sattar (Glasgow, GB)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Professor Naveed Sattar

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

47 presentations

10 followers

6 more presentations in this session

Associations of TyG Index and TyG-obesity-related parameters to cardiovascular disease

Speaker: Associate Professor L. Bikdelu (Mashhad, IR)

Comprehending the genetic obesity basis could help in cardiometabolic disease prevention in women

Speaker: Doctor D. Sa (Funchal, PT)

Prevalence, risk factors, and time-trends in abdominal obesity in 36 countries in the WHO African region from 2003 to 2022: a study of 53 WHO STEPS surveys representing 156 million adults

Speaker: Doctor K. Agboyibor (Paris, FR)

Access

Abstract

Slides

New pediatric waist-to-height ratio adiposity cutoff predicts adulthood hypertension: analysis of 7243 participants from NHANES 2021-2023

Speaker: Doctor D. Corsi (New Brunswick, US)

How genetic variants and excess of weight influence risk of coronary artery disease

Speaker: Doctor G. Bettencourt Abreu (Funchal, PT)

Access the full session

Obesity (1)

Speakers: Professor N. Sattar, Associate Professor L. Bikdelu, Doctor D. Sa, Doctor K. Agboyibor, Doctor D. Corsi...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources